Literature DB >> 23682558

Anti-transforming growth factor-β therapy in patients with myelofibrosis.

John Mascarenhas1, Timmy Li, Lonette Sandy, Carrie Newsom, Bruce Petersen, James Godbold, Ronald Hoffman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23682558     DOI： 10.3109/10428194.2013.805329

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  26 in total

1.  Efficacy of ALK5 inhibition in myelofibrosis.

Authors:  Lanzhu Yue; Matthias Bartenstein; Wanke Zhao; Wanting Tina Ho; Ying Han; Cem Murdun; Adam W Mailloux; Ling Zhang; Xuefeng Wang; Anjali Budhathoki; Kith Pradhan; Franck Rapaport; Huaquan Wang; Zonghong Shao; Xiubao Ren; Ulrich Steidl; Ross L Levine; Zhizhuang Joe Zhao; Amit Verma; Pearlie K Epling-Burnette
Journal:  JCI Insight       Date:  2017-04-06

Review 2.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

Review 3.  Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.

Authors:  Archana Agarwal; Kerry Morrone; Matthias Bartenstein; Zhizhuang Joe Zhao; Amit Verma; Swati Goel
Journal:  Stem Cell Investig       Date:  2016-02-26

Review 4.  Management of Myelofibrosis-Related Cytopenias.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 5.  New Concepts of Treatment for Patients with Myelofibrosis.

Authors:  Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

6.  Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells.

Authors:  Peng Wang; Esra Karakose; Hongtao Liu; Ethan Swartz; Courtney Ackeifi; Viktor Zlatanic; Jessica Wilson; Bryan J González; Aaron Bender; Karen K Takane; Lillian Ye; George Harb; Felicia Pagliuca; Dirk Homann; Dieter Egli; Carmen Argmann; Donald K Scott; Adolfo Garcia-Ocaña; Andrew F Stewart
Journal:  Cell Metab       Date:  2018-12-20       Impact factor: 27.287

Review 7.  Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.

Authors:  Claire N Harrison; Donal P McLornan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

8.  Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

Authors:  Ilaria Ceglia; Amylou C Dueck; Francesca Masiello; Fabrizio Martelli; Wu He; Giulia Federici; Emanuel F Petricoin; Ann Zeuner; Camelia Iancu-Rubin; Rona Weinberg; Ronald Hoffman; John Mascarenhas; Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2016-08-31       Impact factor: 3.084

Review 9.  Novel Therapies for Myelofibrosis.

Authors:  Kristen Pettit; Olatoyosi Odenike
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 10.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.